Jobs
-
Theravance Biopharma and Mylan have announced that a 12-month Phase 3 safety study of nebulized revefenacin (TD-4208) showed that the drug was well tolerated, with low rates of adverse events and serious adverse events that… Read more . . .
-
Opiant Pharmaceuticals has announced results from a Phase 1 trial of OPNT002 intranasal naltrexone, which it is developing for the treatment of alcohol use disorder (AUD). According to the company, which recently announced that it… Read more . . .
-
Dewmar International says that it has filed a provisional patent application titled “Cannabinoid Formulation to Treat Lung Cancer” with the United States Patent and Trademark Office (USPTO). The companies current brands include “Kush Cakes” psychedelic… Read more . . .
-
Samumed has announced positive results from a Phase I trial of an inhalation solution of its novel Wnt signaling modulator SM04646, which the company is developing for the treatment of idiopathic pulmonary fibrosis (IPF). The… Read more . . .
-
Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray. Meda’s NDA for Dymista was approved by the FDA for the treatment of allergic… Read more . . .
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the reclassification of Nasonex mometasone furoate nasal spray from a “POM,” or “prescription only medicine,” to a “P” medicine, available over the counter at… Read more . . .
-
Sunovion has announced that it has agreed to divest US rights to the Alvesco ciclesonide MDI for the treatment of asthma and the Omnaris and Zetonna ciclesonide nasal sprays for the treatment of allergic rhinitis… Read more . . .
-
MannKind Corporation has announced the appointment of Patrick McCauley as Chief Commercial Officer, effective immediately. McCauley was most recently Area VP, West US, Urulogy/PCP Sales for Astellas Pharma and had served in various sales and… Read more . . .
-
During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company’s manufacturing facility in Sydney, which he called “really a… Read more . . .
-
Functional respiratory imaging (FRI) specialist Fluidda has requested a Critical Path Innovation Meeting (CPIM) with the FDA as part of an initiative for approval of its FRI technology as a biomarker, the company said. According… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA